pp-099 Tablets

Indication: Relapsed/refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other B‑cell malignancies in adults with prior lines of therapy Clinical stage: Clinical development — ongoing Phase 1/2 global studies with plans for Phase 3 initiation Modality: Small molecule proteolysis targeting chimera (PROTAC/CDAC) Mechanism / Target: Bruton's tyrosine kinase (BTK) targeting via induced protein degradation to overcome resistance mechanisms to BTK inhibitors Route / form: Oral administration (tablet/capsule formulation in development) Differentiation: First‑in‑class oral BTK degrader designed to degrade both wild‑type and mutant forms of BTK with potential to address resistance to conventional BTK inhibitors and treat multiple B‑cell malignancy subtypes